Adverse Effects of Danazol in Pregnancy

Editorials1 May 1982Adverse Effects of Danazol in PregnancyANNE COLSTON WENTZ, M.D.ANNE COLSTON WENTZ, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-5-672 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDanazol, an impeded androgen, anabolic steroid, and effective inhibitor of the stimulation by follicle stimulating hormone of folliculogenesis, has achieved a deserved reputation as the preferred medical treatment for endometriosis; in addition, it is effective in treating cystic breast disease and has been used to prevent hereditary angioneurotic edema and excessive menstrual blood loss in ovulating women. In a "Drugs Five Years Later" article published in this issue (1), Madanes and Farber provide a broad view of danazol's place in today's practice. Because the recommended dose of at least 600 mg/d is associated with androgenic and antiestrogenic side effects, the...References1. MADANESFARBER AM. Danazol. Ann Intern Med. 1982;96:625-30. LinkGoogle Scholar2. COLLEGREENBLATT MR. Contraceptive properties of danazol. J Reprod Med. 1976;17:98-102. MedlineGoogle Scholar3. GREENBLATTOETTINGERBORENSTEINBOHLER RMRC. Influence of danazol (100 mg) on conception and contraception. J Reprod Med. 1974;13:201-3. MedlineGoogle Scholar4. LAUERSENWILSON NK. Evaluation of danazol as an oral contraceptive. Obstet Gynecol. 1977;50:91-6. MedlineGoogle Scholar5. DUCKKATAYAMA SK. Danazol may cause female pseudohermaphroditism. Fertil Steril. 1981;35:230-1. CrossrefMedlineGoogle Scholar6. HAMMONDTALBERT ML. Danazol's role in gynecologic practice. Obstet Gynecol. 1981;18:85-90. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ANNE COLSTON WENTZ, M.D.Affiliations: Division of Reproductive Endocrinology Vanderbilt University Nashville, Tennessee PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and updateThe international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and updateManagement of hereditary angioedema in pediatric, pregnant, and breast-feeding patients: An expert opinionEmerging corticosteroid delivery platforms for treatment of diabetic macular edemaManagement of patients with hereditary angio-oedema in dental, oral, and maxillofacial surgery: a reviewThe international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and updateThe international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and updateHemolysis and ThrombocytopeniaHormonal Treatment of Fibrocystic DiseaseAsthma and Allergy in PregnancyAmbigüedad sexual por exposición a DANAZOLGoserelin, an LH-RH Agonist, in the Treatment of Women With Fibrocystic Mastopathy. a Pilot StudyManagement of breast pain and nodularityDetermination of Danazol in Plasma by High Performance Liquid ChromatographySex hormones and related compounds, including oral contraceptivesInherited disorders of complementDanazol for the Treatment of Idiopathic Thrombocytopenic Purpura 1 May 1982Volume 96, Issue 5Page: 672-673KeywordsAndrogensBloodDrugsEdemaFollicle stimulating hormoneGenetic diseasesPregnancy ePublished: 1 December 2008 Issue Published: 1 May 1982 PDF downloadLoading ...